DBV Technologies (DBVT) Capital Expenditures (2016 - 2026)
DBV Technologies (DBVT) reported Capital Expenditures of $400000.0 for Q1 2026, up 7.24% on a QoQ basis from $373000.0 in Q4 2025.
DBV Technologies (DBVT) has 11 years of Capital Expenditures data on file, last reported at $400000.0 in Q1 2026.
- Quarterly Capital Expenditures changed N/A year-over-year to $400000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $932000.0 (down 7.08% YoY) and the FY2025 annual result came in at $532000.0, down 77.25% from the prior year.
- Capital Expenditures grew to $400000.0 in Q1 2026 per DBVT's latest filing, from $373000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.3 million in Q1 2024 and bottomed at -$125000.0 in Q4 2024.
- The 5-year median for Capital Expenditures is $201000.0 (2022), against an average of $293812.5.
- The widest annual swing landed in 2022, when Capital Expenditures soared 2969.23%; it then tumbled 135.51% in 2024.
- Tracing DBVT's Capital Expenditures over 5 years: stood at $12000.0 in 2022, then soared by 2833.33% to $352000.0 in 2023, then plunged by 135.51% to -$125000.0 in 2024, then jumped by 398.4% to $373000.0 in 2025, then rose by 7.24% to $400000.0 in 2026.
- Per Business Quant, the three latest DBVT Capital Expenditures figures stand at $400000.0 (Q1 2026), $373000.0 (Q4 2025), and $117000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | 400,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 400,000.00 |
| Mar 31, 2026 | 400,000.00 |
| Dec 31, 2025 | 373,000.00 |
| Dec 31, 2025 | 373,000.00 |
| Sep 30, 2025 | 117,000.00 |
| Sep 30, 2025 | 117,000.00 |
| Jun 30, 2025 | 42,000.00 |
| Jun 30, 2025 | 42,000.00 |
| Dec 31, 2024 | -125,000.00 |
| Dec 31, 2024 | -125,000.00 |
| Sep 30, 2024 | 396,000.00 |
| Sep 30, 2024 | 396,000.00 |
| Jun 30, 2024 | 732,000.00 |
| Jun 30, 2024 | 732,000.00 |
| Mar 31, 2024 | 1.34 Mn |
| Mar 31, 2024 | 1.34 Mn |
| Dec 31, 2023 | 352,000.00 |
| Dec 31, 2023 | 352,000.00 |
| Sep 30, 2023 | 50,000.00 |
| Sep 30, 2023 | 50,000.00 |
| Jun 30, 2023 | 164,000.00 |
| Jun 30, 2023 | 164,000.00 |
| Mar 31, 2023 | 111,000.00 |
| Mar 31, 2023 | 111,000.00 |
| Dec 31, 2022 | 12,000.00 |
| Dec 31, 2022 | 12,000.00 |
| Sep 30, 2022 | 373,000.00 |
| Sep 30, 2022 | 373,000.00 |
| Jun 30, 2022 | 238,000.00 |
| Jun 30, 2022 | 238,000.00 |
| Mar 31, 2022 | 131,000.00 |
| Mar 31, 2022 | 131,000.00 |
| Dec 31, 2021 | 910,000.00 |
| Dec 31, 2021 | 910,000.00 |
| Sep 30, 2021 | -13,000.00 |
| Sep 30, 2021 | -13,000.00 |
| Jun 30, 2021 | -171,000.00 |
| Jun 30, 2021 | -171,000.00 |
| Mar 31, 2021 | 184,000.00 |
| Mar 31, 2021 | 184,000.00 |
| Jun 30, 2020 | 616,000.00 |
| Jun 30, 2020 | 616,000.00 |
| Mar 31, 2020 | 816,000.00 |
| Mar 31, 2020 | 816,000.00 |
| Dec 31, 2019 | 6.39 Mn |
| Dec 31, 2019 | 6.39 Mn |
| Sep 30, 2019 | -4.01 Mn |
| Sep 30, 2019 | -4.01 Mn |
| Jun 30, 2019 | -2.38 Mn |
| Jun 30, 2019 | -2.38 Mn |
| Dec 31, 2018 | -5.38 Mn |
| Dec 31, 2018 | -5.38 Mn |
| Sep 30, 2018 | -4.43 Mn |
| Sep 30, 2018 | -4.43 Mn |
| Jun 30, 2018 | -594,335.32 |
| Jun 30, 2018 | -594,335.32 |
| Dec 31, 2017 | -8.53 Mn |
| Dec 31, 2017 | -8.53 Mn |
| Dec 31, 2016 | -8.63 Mn |
| Dec 31, 2016 | -8.63 Mn |